Home > Insider Trading > Filing (0000899243-23-009600)

Filing Details

Accession Number:: 0000899243-23-009600
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2023-03-24 18:45:03
Reporting Period:: 2023-03-16

Accepted Time:: 2023-03-24 18:45:03
Original Submission Date:: 2023-03-20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1658551	Amylyx Pharmaceuticals Inc.	AMLX	()	4/A

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1358266	D Patrick Yeramian	C/O Amylyx Pharmaceuticals, Inc. 43 Thorndike Street Cambridge MA 02141	Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-03-16	2,789	$0.33	207,088	No	4	M	Direct
Common Stock	Acquisiton	2023-03-16	30,041	$0.37	237,129	No	4	M	Direct
Common Stock	Acquisiton	2023-03-16	16,748	$6.88	253,877	No	4	M	Direct
Common Stock	Disposition	2023-03-16	52,211	$31.85	201,666	No	4	S	Direct
Common Stock	Disposition	2023-03-16	2,416	$32.43	199,250	No	4	S	Direct
Common Stock	Acquisiton	2023-03-16	9,167	$0.00	208,417	No	4	A	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	A	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Acquisiton	2023-03-16	41,250	$0.00	41,250	$32.08
Common Stock	Stock Option (right to buy)	Disposition	2023-03-16	2,789	$0.00	2,789	$0.33
Common Stock	Stock Option (right to buy)	Disposition	2023-03-16	30,041	$0.00	30,041	$0.37
Common Stock	Stock Option (right to buy)	Disposition	2023-03-16	16,748	$0.00	16,748	$6.88

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
41,250	2033-03-16	No	4	A	Direct
0	2028-02-16	No	4	M	Direct
62,466	2029-03-18	No	4	M	Direct
48,252	2031-02-21	No	4	M	Direct

Footnotes

On March 16, 2023, the Reporting Person filed a Form 4 (the "Original Form 4") which inadvertently omitted the exercise of an aggregate of 49,578 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer ("Common Stock") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4.
These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2022.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.26 to $32.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.28 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a "RSU"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date.
1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
The shares subject to such option are vested and currently exercisable.
As of the date of this filing, 39,688 shares subject to the option are vested and exercisable. 52,819 shares subject to such option vest and become exercisable in substantially equal monthly installments until November 26, 2023.
16,256 shares underlying this option vested on February 19, 2022, with the remaining shares vesting in monthly installments of 1,354 shares thereafter.